Sinopec and BASF Mutually Recognize Product Carbon Footprint Accounting Methods, Sets New Benchmark for Industry Standardization

Sinopec and BASF Mutually Recognize Product Carbon Footprint Accounting Methods, Sets New Benchmark for Industry Standardization

NINGBO, China, Oct. 31, 2025 /PRNewswire/ -- China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec") and BASF jointly declared the alignment on the core requirements of carbon footprint accounting methods and reached framework-based mutual...

Hope in Syria: Education Cannot Wait investments support teacher training and continued learning for displaced children in Syria

Hope in Syria: Education Cannot Wait investments support teacher training and continued learning for displaced children in Syria

NEW YORK, Oct. 24, 2025 /PRNewswire/ -- In the heart of a refugee camp in Syria, one teacher stands tall at the head of her classroom – offering a lifeline to children eager to learn despite the unrelenting challenges they face. Teacher Rudayfah...

Fruit Attraction 2025 Strengthens Its Global Leadership with a Record 121,137 Trade Professionals

Fruit Attraction 2025 Strengthens Its Global Leadership with a Record 121,137 Trade Professionals

MADRID, Oct. 20, 2025 /PRNewswire/ -- Fruit Attraction 2025, organised by IFEMA MADRID and FEPEX, closed its 17th edition with record-breaking participationfigures, welcoming 121,137 trade visitors from 152 countries, representing an 3% increase in...

Turfan, Xinjiang: Accelerating Construction of 10-Million-Kilowatt-Level New Energy Base

Turfan, Xinjiang: Accelerating Construction of 10-Million-Kilowatt-Level New Energy Base

TURFAN, China, June 11, 2025 /PRNewswire/ -- On June 11th, Turfan's installed capacity of new energy sources reached 9.035 million kilowatts (kW), accounting for 74.2% of its total power generation capacity. The region is expected to complete the...

Ampace Andes Powers Through Extreme Challenges at 7,000 Meters on Mount Everest

Ampace Andes Powers Through Extreme Challenges at 7,000 Meters on Mount Everest

NEW YORK, June 10, 2025 /PRNewswire/ -- Veteran mountaineer and extreme landscape photographer Gao Li—marking his tenth year of Himalayan expeditions—recently reached Mount Everest's summit (8,848.86m) for the third time. An accomplished explorer of...

The installed capacity of new energy in Turfan has surpassed 9 million kilowatts, accounting for 74.2% of the total installed capacity of power sources

The installed capacity of new energy in Turfan has surpassed 9 million kilowatts, accounting for 74.2% of the total installed capacity of power sources

TURFAN, China, May 29, 2025 /PRNewswire/ -- On May 29th, State Grid Turfan Power Supply Company announced that the installed capacity of new energy in Turfan reached 9.035 million kilowatts, representing 74.2% of the total installed capacity of...

Visionary Holdings' Changle Shuang Carries Out Biotechnology Health Public Welfare Activities for Society

Visionary Holdings' Changle Shuang Carries Out Biotechnology Health Public Welfare Activities for Society

TORONTO, May 27, 2025 /PRNewswire/ -- On May 23, 2025, Changle Shuang, a subsidiary of Visionary Holdings (Nasdaq: GV), officially reached a strategic partnership with the Guangzhou Jianjia Charity Foundation in Guangzhou. The two parties signed a...

Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ‌Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ‌Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希®), the first...

The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China

The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China

The results showed that the SOFA scores of the drug treatment groups on the 7th day were significantly lower than those of the baseline, especially in the high-dose group, where the decrease was significantly greater than that in the placebo group,...

Thailand's First Quarter Investment Applications Almost Double to 431.2 Billion Baht Boosted by Fivefold Increase in Digital Sector, BOI Says

Thailand's First Quarter Investment Applications Almost Double to 431.2 Billion Baht Boosted by Fivefold Increase in Digital Sector, BOI Says

BANGKOK, April 30, 2025 /PRNewswire/ -- The value of applications for investment promotion in Thailand in the first quarter of 2025 amounted to 431.2 billion baht (USD 12.9 billion), an increase of 97% from the same period of last year, led by large...

  • 1
  • 2
  • 3
  • menu
    menu